Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

481 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of platinum combination chemotherapy plus pembrolizumab versus platinum combination chemotherapy plus nivolumab-ipilimumab for treatment-naive advanced non-small-cell lung cancer in Japan (JCOG2007): an open-label, multicentre, randomised, phase 3 trial.
Shiraishi Y, Nomura S, Sugawara S, Horinouchi H, Yoneshima Y, Hayashi H, Azuma K, Hara S, Niho S, Morita R, Yamaguchi M, Yokoyama T, Yoh K, Kurata T, Okamoto H, Okamoto M, Kijima T, Kasahara K, Fujiwara Y, Murakami S, Kanda S, Akamatsu H, Takemoto S, Kaneda H, Kozuki T, Ando M, Sekino Y, Fukuda H, Ohe Y, Okamoto I. Shiraishi Y, et al. Among authors: takemoto s. Lancet Respir Med. 2024 Nov;12(11):877-887. doi: 10.1016/S2213-2600(24)00185-1. Epub 2024 Aug 16. Lancet Respir Med. 2024. PMID: 39159638 Clinical Trial.
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: takemoto s. Eur Respir J. 2022 Dec 15;60(6):2200380. doi: 10.1183/13993003.00380-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35361630 Free article. Clinical Trial.
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, Yamaguchi T, Masuda T, Yokoyama T, Otsubo K, Haratani K, Hayakawa D, Oki M, Takemoto S, Ozaki T, Akashi Y, Hata A, Hashimoto H, Yamamoto N, Nakagawa K. Uemura T, et al. Among authors: takemoto s. Cancer Med. 2023 Dec;12(23):21097-21110. doi: 10.1002/cam4.6668. Epub 2023 Nov 10. Cancer Med. 2023. PMID: 37948122 Free PMC article.
Prediction of prognosis in lung cancer using machine learning with inter-institutional generalizability: A multicenter cohort study (WJOG15121L: REAL-WIND).
Fujimoto D, Hayashi H, Murotani K, Toi Y, Yokoyama T, Kato T, Yamaguchi T, Tanaka K, Miura S, Tamiya M, Tachihara M, Shukuya T, Tsuchiya-Kawano Y, Sato Y, Ikeda S, Sakata S, Masuda T, Takemoto S, Otsubo K, Shibaki R, Makino M, Okamoto I, Yamamoto N. Fujimoto D, et al. Among authors: takemoto s. Lung Cancer. 2024 Aug;194:107896. doi: 10.1016/j.lungcan.2024.107896. Epub 2024 Jul 18. Lung Cancer. 2024. PMID: 39043076
A phase II study of weekly carboplatin and concurrent radiotherapy in older adults with locally advanced non-small cell lung cancer (LOGIK1902).
Harada T, Sasaki T, Ishii H, Takemoto S, Hisamatsu Y, Saito H, Yoneshima Y, Komiya K, Kashiwabara K, Naoki K, Ogawa T, Takeoka H, Saruwatari K, Ito K, Tsuchiya-Kawano Y, Mizuno K, Shimose T, Shioyama Y, Okamoto I. Harada T, et al. Among authors: takemoto s. Thorac Cancer. 2024 Oct;15(29):2128-2135. doi: 10.1111/1759-7714.15444. Epub 2024 Sep 8. Thorac Cancer. 2024. PMID: 39245951 Free PMC article. Clinical Trial.
Favorable impact of azithromycin on patients in the intensive care unit with coronavirus disease 2019: Insights from the first wave using a Japanese database.
Tokito T, Kido T, Sato S, Tashiro M, Miyashita R, Ozasa M, Okuno D, Yura H, Takemoto S, Takazono T, Ishimoto H, Sakamoto N, Tanaka T, Obase Y, Ishimatsu Y, Nishino T, Fushimi K, Izumikawa K, Mukae H. Tokito T, et al. Among authors: takemoto s. Respir Med. 2024 Nov-Dec;234:107834. doi: 10.1016/j.rmed.2024.107834. Epub 2024 Oct 10. Respir Med. 2024. PMID: 39395617
Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.
Mizoguchi K, Nakamura Y, Sano K, Sato S, Ikegami Y, Motoshima K, Takemoto S, Ogawara D, Senju H, Sugasaki N, Ikeda T, Yamaguchi H, Nakatomi K, Fukuda M, Izumikawa K, Mukae H. Mizoguchi K, et al. Among authors: takemoto s. Cancer Chemother Pharmacol. 2016 Aug;78(2):377-82. doi: 10.1007/s00280-016-3097-4. Epub 2016 Jun 23. Cancer Chemother Pharmacol. 2016. PMID: 27339148 Clinical Trial.
Phase I study of pemetrexed and concurrent radiotherapy for previously untreated elderly patients with locally advanced non-squamous non-small cell lung cancer.
Takemoto S, Nakamura Y, Fukuda M, Senju H, Gyotoku H, Taniguchi H, Shimada M, Ikeda T, Yamaguchi H, Nakatomi K, Hayashi N, Soda H, Mukae H. Takemoto S, et al. Thorac Cancer. 2017 Nov;8(6):577-581. doi: 10.1111/1759-7714.12483. Epub 2017 Aug 3. Thorac Cancer. 2017. PMID: 28771961 Free PMC article. Clinical Trial.
Phase II trial of a non-platinum triplet for patients with advanced non-small cell lung carcinoma (NSCLC) overexpressing ERCC1 messenger RNA.
Takemoto S, Nakamura Y, Gyoutoku H, Senju H, Ogawara D, Ikeda T, Yamaguchi H, Kitazaki T, Nakano H, Nakatomi K, Tomari S, Sato S, Nagashima S, Fukuda M, Mukae H. Takemoto S, et al. Thorac Cancer. 2019 Mar;10(3):452-458. doi: 10.1111/1759-7714.12958. Epub 2019 Jan 9. Thorac Cancer. 2019. PMID: 30628188 Free PMC article. Clinical Trial.
481 results